XORTX Therapeutics Inc (XRTX)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XORTX Announces Closing of US$5 Million Public Offering

CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...

E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XORTX Announces US$5 Million Public Offering

CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”...

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]